

MDL - RSV/Influenza/Covid-19 (RIC) Test

Healthcare Provider Information Sheet

Test Information

The MDL RSV/Influenza/SARS-CoV-2 (RIC) assay is a multiplexed reverse transcription polymerase chain reaction (RT-PCR) test that is validated for use with all upper respiratory samples in people of all ages. The test targets multiple regions of the SARS-CoV-2 organism (spike and nucleocapsid) and has 100% homology for all known strains of SARS-CoV-2. Additionally, the test targets a shared region of Respiratory syncytial virus (RSV) A and B as well as a shared region of Influenza A and B. If a patient sample has detectable RSV A/B or Influenza A/B, the result will state positive for RSV or positive for Influenza without calling a subtype, as we cannot distinguish between the subtypes by this assay. This assay will not detect Influenza C.

Sample Collection and Submission

Samples should be collected by trained healthcare providers using appropriate infection control precautions. Guidance should be sought by viewing the CDC website for sample collection